Education
About Us
Working with TipRanks
Follow Us
Nanobiotix (NBTX)
NASDAQ:NBTX
NBTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.76 - $7.51
Previous CloseN/A
Volume23.08K
Average Volume (3M)14.34K
Market Cap
$154.42M
Enterprise ValueN/A
Total Cash (Recent Filing)€12.36M
Total Debt (Recent Filing)€1.43M
Price to Earnings (P/E)―
Beta0.14
Next Earnings
May 14, 2025EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding47,133,327
10 Day Avg. Volume16,601
30 Day Avg. Volume14,336
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.32
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6.83Price Target Upside114.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Nanobiotix News
PremiumCompany Announcements
Nanobiotix Discloses Managerial Share Acquisitions in April 2025
PremiumCompany Announcements
Nanobiotix SA ADR Reports 2024 Financial Results
PremiumCompany Announcements
Nanobiotix Reports 2024 Progress and Financial Results
PremiumCompany Announcements
Nanobiotix to Announce 2024 Financial Results and Host Conference Call---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe collaboration with MD Anderson Cancer Center is exploring the potential of NBTXR3 in a range of additional tumor types, including pancreatic and esophageal cancer, which could expand the drug's applicability and market reach.
Financial StabilityA recent amendment of its licensing agreement with JNJ extends the company's cash runway to mid-2026, safeguarding the company's path through the interim analysis of the NANORAY-312 trial.
Strategic PartnershipsThe partnership with JNJ and the ongoing collaboration are seen as supportive, enhancing the credibility and potential success of NBTXR3.
Bears Say
Clinical And Commercial RisksClinical and commercial risks are acknowledged for the novel radioenhancer NBTXR3 and risks related to the company’s balance sheet.
Financial ConcernsInvestor focus is expected to remain on the company's cash runway and ongoing concerns about the balance sheet, implying financial stability is a key concern for stakeholders.
---
Ownership Overview
―
Insiders
0.01% Mutual Funds
12.60% Other Institutional Investors
87.39% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NBTX FAQ
What was Nanobiotix’s price range in the past 12 months?
Nanobiotix lowest stock price was $2.76 and its highest was $7.51 in the past 12 months.
What is Nanobiotix’s market cap?
Nanobiotix’s market cap is $154.42M.
When is Nanobiotix’s upcoming earnings report date?
Nanobiotix’s upcoming earnings report date is May 14, 2025 which is in 31 days.
How were Nanobiotix’s earnings last quarter?
Nanobiotix released its earnings results on Apr 02, 2025. The company reported -$1.09 earnings per share for the quarter, missing the consensus estimate of -$0.555 by -$0.535.
Is Nanobiotix overvalued?
According to Wall Street analysts Nanobiotix’s price is currently Undervalued.
Does Nanobiotix pay dividends?
Nanobiotix does not currently pay dividends.
What is Nanobiotix’s EPS estimate?
Nanobiotix’s EPS estimate is -0.56.
How many shares outstanding does Nanobiotix have?
Nanobiotix has 47,133,327 shares outstanding.
What happened to Nanobiotix’s price movement after its last earnings report?
Nanobiotix reported an EPS of -$1.09 in its last earnings report, missing expectations of -$0.555. Following the earnings report the stock price went down -0.588%.
Which hedge fund is a major shareholder of Nanobiotix?
Currently, no hedge funds are holding shares in NBTX
---
Nanobiotix Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.83 (114.78% Upside)
$6.83 (114.78% Upside)
Hedge Fund Trend
Decreased
By 289.0K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.08%
12-Months-Change
Fundamentals
Return on Equity
2152.93%
Trailing 12-Months
Asset Growth
110.74%
Trailing 12-Months
Company Description
Nanobiotix
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
---
NBTX Company Deck
---
NBTX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant strategic progress with the JNJ collaboration and pipeline advancements, along with a strong financial strategy to extend cash runway. However, financial performance showed challenges with negative revenue and increased net loss.Read More>---
NBTX Stock 12 Month Forecast
Average Price Target
$6.83
▲(114.78% Upside)
Technical Analysis
TG Therapeutics
―
Immunic
―
Brainstorm Cell Therapeutics
―
Cellectis SA
―
ADC Therapeutics
―
Best Analysts Covering NBTX
1 Year
1 Year Success Rate
1/9 ratings generated profit
1 Year Average Return
-27.77%
reiterated a buy rating 10 days ago
Copying Jonathan Chang's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -27.77% per trade.
---